Dashboard PDUFA PDUFA History Dilution Watch Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Track ONCY with free AI briefings, catalyst countdowns, and dilution alerts.

ONCY · Oncolytics Biotech Inc.

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$4.1M Cash on Hand

1.6mo Cash Runway

6.9% Short Interest

$4.15 Analyst Target (6)

Follow ONCY by email Get an email when ONCY pushes back a promised milestone, files for a stock offering or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about ONCY, unsubscribe in one click. Privacy

🧪 Trial & FDA Catalysts

Jul 2027 · Phase 1/2 · Active Trial · A Study in Advanced or Metastatic Gastrointestinal Cancers Exploring Treatment Combination
Registry primary completion date, not a results date
Aug 2027 · Phase 2 · Recruiting · FOLFIRI and Bevacizumab With or Without Pelareorep for Second-Line Treatment of Metastatic
Registry primary completion date, not a results date
Jun 2025 · Phase 2 · Active Trial · INCMGA00012 and Pelareorep for the Treatment of Metastatic Triple Negative Breast Cancer,
Registry date passed, readout not confirmed

📊 Drug Pipeline

Drug	Indication	Most advanced trial	Status
Pelareorep	Carcinoma, Squamous Cell of the Head and Neck	Phase 3 · NCT01166542	Completed
Trifluridine and Tipiracil Hydrochloride	Anal Cancer Metastatic	Phase 1/2 · NCT07280377	Active not recruiting
mFOLFIRINOX Treatment Regimen	Anal Cancer Metastatic	Phase 1/2 · NCT07280377	Active not recruiting
Nab-paclitaxel	Anal Cancer Metastatic	Phase 1/2 · NCT07280377	Active not recruiting
FOLFIRI	Ras-mutated Metastatic Colorectal Cancer	Phase 2 · NCT07446322	Recruiting
Fluorouracil	Pancreatic Adenocarcinoma	Phase 1 · NCT02620423	Completed
Cytotoxic Chemotherapeutic Agent	Pancreatic Adenocarcinoma	Phase 1 · NCT02620423	Completed
Lenalidomide or Pomalidomide	Multiple Myeloma	Phase 1 · NCT03015922	Unknown
Irinotecan	KRAS Mutant Metastatic Colorectal Cancer	Phase 1 · NCT01274624	Completed

Also used in these trials (approved or third-party drugs, not ONCY's own candidates): Carboplatin, Paclitaxel, Atezolizumab, Retifanlimab, Pemetrexed Disodium, Gemcitabine Hydrochloride, Bevacizumab, Docetaxel Anhydrous, Avelumab, Dexamethasone, Bortezomib, Carfilzomib.

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

ONCY holds $4.1M in cash and short-term investments (as of Jun 30, 2026) and burns about $7.7M/quarter from operations, an estimated runway of 1.6 months at that rate (BioRadar estimate, not company guidance).

Dilution pressure: 80 · High

Cash runway 2 months +40
ATM program on file since Apr 2026 +15
Shelf registration (S-3, Apr 2026) +10
Going-concern doubt in the latest 10-Q +15These conditions raise substantial doubt about our ability to continue as a going concern. 10-Q, Aug 2026

Recent financing filings on SEC EDGAR:

Apr 6, 2026 · ATM program, up to $75M · 424B5
Apr 1, 2026 · Shelf registration, up to $250M · S-3
Oct 17, 2025 · ATM program, up to $50M · 424B5
Aug 22, 2025 · Shelf registration · F-3

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when ONCY files for a raise →

👥 Who Owns ONCY

Insiders 1.9% Institutions 7.9% Public and other holders 90.2%

Holder	Type	Shares	% of shares	As of
Anson Funds Management LP	Institution (13G, 5%+)	7,649,050	6.00%	2025-09-30
Marshall Wace LLP	Institution (13F)	745,350	0.58%	2026-06-30
Bernd R. Seizinger Director · +30,000 options	Insider	566,991	0.44%	2026-02-11
Wayne Pisano Director · +30,000 options	Insider	492,414	0.39%	2026-02-12
Kirk Look Chief Financial Officer · +260,000 options	Insider	287,515	0.23%	2026-02-12
Thomas Charles Heineman Chief Medical Officer · +260,000 options	Insider	282,818	0.22%	2026-02-12
Xtx Topco Ltd	Institution (13F)	260,903	0.20%	2026-06-30
Seeds Investor LLC	Institution (13F)	258,306	0.20%	2026-06-30
International Assets Investment Manageme	Institution (13F)	201,260	0.16%	2026-06-30
Connective Capital Management LLC	Institution (13F)	185,712	0.15%	2026-06-30
Angela Holtham Director · +30,000 options	Insider	183,639	0.14%	2026-01-01
Goldman Sachs Group Inc	Institution (13F)	169,898	0.13%	2026-06-30

Share count 127,510,505 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the largest 13F holders (13F quarter ending 2026-06-30). Sources have different dates, so the split is approximate. Source: SEC EDGAR.

📈 Recent Insider Activity (Form 4)

Trade date	Insider	Transaction	Shares	Price	Owned after
2026-06-01 filed 2026-06-03	Glover Stephen C.	Option award (A)	96,000	–	–
2026-06-01 filed 2026-06-03	Brown Deborah Margaret	Option award (A)	30,000	–	–
2026-06-01 filed 2026-06-03	RIGBY JONATHAN	Option award (A)	30,000	–	–
2026-06-01 filed 2026-06-03	Pisano Wayne	Option award (A)	30,000	–	–
2026-06-01 filed 2026-06-03	Holtham Angela	Option award (A)	30,000	–	–

Only open-market purchases (P) and sales (S) are trading decisions. Awards (A), option exercises (M) and tax withholding (F) are compensation mechanics. Source: SEC Form 4.

Get the full ONCY picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for ONCY and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z